Biohaven Statistics
Total Valuation
Biohaven has a market cap or net worth of $1.44 billion. The enterprise value is $1.41 billion.
Important Dates
The last earnings date was Monday, March 2, 2026, after market close.
| Earnings Date | Mar 2, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Biohaven has 150.42 million shares outstanding. The number of shares has increased by 17.97% in one year.
| Current Share Class | 150.42M |
| Shares Outstanding | 150.42M |
| Shares Change (YoY) | +17.97% |
| Shares Change (QoQ) | +13.58% |
| Owned by Insiders (%) | 10.80% |
| Owned by Institutions (%) | 83.03% |
| Float | 123.89M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 132.64 |
| PB Ratio | 24.43 |
| P/TBV Ratio | 44.64 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.18, with a Debt / Equity ratio of 5.47.
| Current Ratio | 3.18 |
| Quick Ratio | 2.75 |
| Debt / Equity | 5.47 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -310.75% and return on invested capital (ROIC) is -111.14%.
| Return on Equity (ROE) | -310.75% |
| Return on Assets (ROA) | -83.02% |
| Return on Invested Capital (ROIC) | -111.14% |
| Return on Capital Employed (ROCE) | -211.13% |
| Weighted Average Cost of Capital (WACC) | 19.76% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.70M |
| Employee Count | 274 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Biohaven has paid $1.44 million in taxes.
| Income Tax | 1.44M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -67.43% in the last 52 weeks. The beta is 3.53, so Biohaven's price volatility has been higher than the market average.
| Beta (5Y) | 3.53 |
| 52-Week Price Change | -67.43% |
| 50-Day Moving Average | 11.46 |
| 200-Day Moving Average | 13.19 |
| Relative Strength Index (RSI) | 35.52 |
| Average Volume (20 Days) | 2,189,667 |
Short Selling Information
The latest short interest is 21.03 million, so 13.98% of the outstanding shares have been sold short.
| Short Interest | 21.03M |
| Short Previous Month | 20.71M |
| Short % of Shares Out | 13.98% |
| Short % of Float | 16.98% |
| Short Ratio (days to cover) | 9.99 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -708.37M |
| Pretax Income | -737.38M |
| Net Income | -738.82M |
| EBITDA | -698.45M |
| EBIT | -708.37M |
| Earnings Per Share (EPS) | -$6.86 |
Full Income Statement Balance Sheet
The company has $319.14 million in cash and $284.61 million in debt, with a net cash position of $34.52 million or $0.23 per share.
| Cash & Cash Equivalents | 319.14M |
| Total Debt | 284.61M |
| Net Cash | 34.52M |
| Net Cash Per Share | $0.23 |
| Equity (Book Value) | 52.07M |
| Book Value Per Share | 0.39 |
| Working Capital | 252.40M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$609.44 million and capital expenditures -$715,000, giving a free cash flow of -$610.15 million.
| Operating Cash Flow | -609.44M |
| Capital Expenditures | -715,000 |
| Free Cash Flow | -610.15M |
| FCF Per Share | -$4.06 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Biohaven does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -17.97% |
| Shareholder Yield | -17.97% |
| Earnings Yield | -51.27% |
| FCF Yield | -42.34% |
Analyst Forecast
The average price target for Biohaven is $28.85, which is 201.15% higher than the current price. The consensus rating is "Buy".
| Price Target | $28.85 |
| Price Target Difference | 201.15% |
| Analyst Consensus | Buy |
| Analyst Count | 14 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |